IP Library Granted Patent US 9,645,139
Granted Patent B2
US 9,645,139 · App. 14/945,629 · Granted May 9, 2017

Neuroprotective chemicals and methods for identifying and using same

Inventors: Steven L. McKnight (Dallas, TX); Joseph M. Ready (Carrollton, TX); Andrew A. Pieper (Iowa City, IA); Gelin Wang (Plano, TX); Ting Han (Dallas, TX)
Assignee: Board of Regents of The University of Texas System
G01N33/5058G01N33/5014G01N33/5038G01N2333/91142
View Patent ↗
Loading inventors, assignments & file history…
Monitor This Case
Get email alerts when status or documents change.
Order Certified Copies
Most orders are placed with the USPTO same day — all within 24 business hours.
Order via The Patent Place →
Pre-filled with this patent's details
Quick Facts
Patent No.
US 9,645,139
App. No.
14/945,629
Granted
May 9, 2017
Kind
B2
Abstract

Provided herein are methods for identifying a compound having cell-protective (e.g., neuroprotective) activity. Compounds identified therefrom are also provided. These compounds can be used to treat various diseases, disorders, or conditions associated with, for example, unwanted cell death.

Claims (113)

1. A method for identifying a compound having cell-protective activity, comprising:

incubating a test compound with a nicotinamide phosphoribosyltransferase (NAMPT);

measuring an activity of the NAMPT; and

identifying the test compound as having cell-protective activity when there is an increase in the activity of the NAMPT compared to a control that is not incubated with the test compound, wherein the test compound is a compound having formula (I):

wherein:

each of R 1 , R 2 , R 3 , and R 4 is independently selected from hydrogen, halo, hydroxyl, sulfhydryl, C 1 -C 6 alkoxy, C 1 -C 6 thioalkoxy, C 1 -C 6 haloalkoxy, C 1 -C 6 thiohaloalkoxy, C 1 -C 6 alkyl, C 1 -C 6 haloalkyl, C 2 -C 6 alkynyl, cyclopropyl, —N 3 , cyano, —NH 2 , —NH(C 1 -C 6 alkyl), —N(C 1 -C 6 alkyl) 2 , —NHC(O)(C 1 -C 6 alkyl), nitro, —C(O)O(C 1 -C 6 alkyl), —C(O)NH 2 , —C(O)NH(C 1 -C 6 alkyl), —C(O)N(C 1 -C 6 alkyl) 2 , —S(O) 2 NH 2 , —S(O) 2 NH(C 1 -C 6 alkyl), and —S(O) 2 N(C 1 -C 6 alkyl) 2 ;

R and R′ are defined according to (1), (2), (3) or (4) below:

(1) R and R′ together with C 2 and C 3 , respectively, form a fused phenyl ring having formula (II):

wherein each of R 5 , R 6 , R 7 , and R 8 is independently selected from hydrogen, halo, hydroxyl, sulfhydryl, C 1 -C 6 alkoxy, C 1 -C 6 thioalkoxy, C 1 -C 6 haloalkoxy, C 1 -C 6 thiohaloalkoxy, C 1 -C 6 alkyl, C 1 -C 6 haloalkyl, C 2 -C 6 alkynyl, cyclopropyl, —N 3 , cyano, —NH 2 , —NH(C 1 -C 6 alkyl), —N(C 1 -C 6 alkyl) 2 , —NHC(O)(C 1 -C 6 alkyl), nitro, —C(O)O(C 1 -C 6 alkyl), —C(O)NH 2 , —C(O)NH(C 1 -C 6 alkyl), —C(O)N(C 1 -C 6 alkyl) 2 , —S(O) 2 NH 2 , —S(O) 2 NH(C 1 -C 6 alkyl), and —S(O) 2 N(C 1 -C 6 alkyl) 2 ; or

(2) R and R′ together with C2 and C3, respectively, form a fused heteroaryl ring containing 6 ring atoms, wherein from 1-2 independently selected ring atoms is N; and wherein said heteroaryl ring is optionally substituted with from 1-2 independently selected R b ; or

(3) R and R′ together with C 2 and C 3 , respectively, form a fused heterocyclic ring containing from 5-6 ring atoms, wherein from 1-2 of the ring atoms is independently selected from N, NH, N(C 1 -C 6 alkyl), NC(O)(C 1 -C 6 alkyl), O, and S; and wherein said heterocyclic ring is optionally substituted with from 1-3 independently selected R a ; or

(4) each of R and R′ is, independently, hydrogen, C 1 -C 6 alkyl, or C 1 -C 6 haloalkyl; each of L 1 and L 2 is, independently, C 1 -C 3 alkylene, which is optionally substituted with from 1-2 independently selected R c ;

A is:

(i) CR A1 R A2 , wherein each of R A1 and R A2 is independently selected from hydrogen, halo, C 1 -C 3 alkyl, OR 9 , wherein R 9 is hydrogen or C 1 -C 3 alkyl that is optionally substituted with hydroxyl or C 1 -C 3 alkoxy, or a double bond formed between A and one of L 1 and L 2 ; or

(ii) C⊚O; or

(iii) C 3 -C 5 cycloalkylene that is (a) substituted with 1 oxo; and (b) optionally further substituted with from 1-4 independently selected R a ; or

(iv) heterocycloalkylene containing from 3-5 ring atoms, wherein from 1-2 of the ring atoms is independently selected from N, NH, N(C 1 -C 3 alkyl), O, and S; and wherein said heterocycloalkylene is (a) substituted with 1 oxo; and (b) is optionally further substituted with from 1-4 independently selected R a ;

Z is:

(i) —NR 10 R 11 ; or

(ii) —C(O)NR 10 R 11 ; or

(iii) —OR 12 ; or

(iv) —S(O) n R 13 , wherein n is 0, 1, or 2; or

(v) heterocycloalkenyl containing from 5-6 ring atoms, wherein from 1-3 of the ring atoms is independently selected from N, NH, N(C 1 -C 6 alkyl), NC(O)(C 1 -C 6 alkyl), O, and S; and wherein said heterocycloalkenyl is optionally substituted with from 1-4 independently selected R a ; or

(vi) C 6 -C 10 aryl that is optionally substituted with from 1-4 independently selected R b ; or

(vii) heteroaryl containing from 5-14 ring atoms, wherein from 1-6 of the ring atoms is independently selected from N, NH, N(C 1 -C 3 alkyl), O, and S; and wherein said heteroaryl is optionally substituted with from 1-4 independently selected R b ; or

(viii) C 8 -C 14 arylcycloalkyl, wherein:

(1) the aryl portion is optionally substituted with from 1-4 independently selected R b , and

(2) the cycloalkyl portion is optionally substituted with from 1-4 independently selected R a ; or

(ix) arylheterocyclyl containing from 8-14 ring atoms, wherein:

(1) the aryl portion from is optionally substituted with from 1-4 independently selected R b , and

(2) from 1-2 of the ring atoms of the heterocyclyl portion is independently selected from N, NH, N(C 1 -C 6 alkyl), NC(O)(C 1 -C 6 alkyl), O, and S; and wherein said heterocyclyl portion is optionally substituted with from 1-3 independently selected R a ; or

(x) heteroarylheterocyclyl containing from 8-14 ring atoms, wherein:

(1) from 1-2 of the ring atoms of the heteroaryl portion is independently selected from N, NH, N(C 1 -C 3 alkyl), O, and S; and wherein said heteroaryl portion is optionally substituted with from 1-3 independently selected R b ; and

(2) from 1-2 of the ring atoms of the heterocyclyl portion is independently selected from N, NH, N(C 1 -C 6 alkyl), NC(O)(C 1 -C 6 alkyl), O, and S; and wherein said heterocyclyl portion is optionally substituted with from 1-3 independently selected R a ; or

(xi) heteroarylcycloalkyl containing from 8-14 ring atoms, wherein:

(1) from 1-2 of the ring atoms of the heteroaryl portion is independently selected from N, NH, N(C 1 -C 3 alkyl), O, and S; and wherein said heteroaryl portion is optionally substituted with from 1-3 independently selected R b ; and

(2) the cycloalkyl portion is optionally substituted with from 1-4 independently selected R a ;

each of R 10 and R 11 is independently selected from the substituents delineated collectively in (a) through (1) below:

(a) hydrogen;

(b) C 6 -C 10 aryl that is optionally substituted with from 1-4 R b ;

(c) heteroaryl containing from 5-14 ring atoms, wherein from 1-6 of the ring atoms is independently selected from N, NH, N(C 1 -C 3 alkyl), O, and S; and wherein said heteroaryl is optionally substituted with from 1-4 R b ;

(d) C 1 -C 6 alkyl or C 1 -C 6 haloalkyl, each of which is optionally substituted with from 1-3 R d ;

(e) —C(O) (C 1 -C 6 alkyl), —C(O)(C 1 -C 6 haloalkyl), —C(O)O(C 1 -C 6 alkyl), —S(O) 2 (C 1 -C 6 alkyl), —S(O) 2 (C 6 -C 10 aryl), or —S(O) 2 (C 1 -C 13 heteroaryl), wherein the C 6 -C 10 aryl and C 1 -C 13 heteroaryl are each independently optionally substituted with 1-4 R b ;

(f) C 2 -C 6 alkenyl or C 2 -C 6 alkynyl;

(g) C 8 -C 14 arylcycloalkyl, wherein:

(1) the aryl portion is optionally substituted with from 1-4 independently selected R b , and

(2) the cycloalkyl portion is optionally substituted with from 1-4 independently selected R a ;

(h) arylheterocyclyl containing from 8-14 ring atoms, wherein:

(1) the aryl portion from is optionally substituted with from 1-4 independently selected R b , and

(2) from 1-2 of the ring atoms of the heterocyclyl portion is independently selected from N, NH, N(C 1 -C 6 alkyl), NC(O)(C 1 -C 6 alkyl), O, and S; and wherein said heterocyclyl portion is optionally substituted with from 1-3 independently selected R a ;

(i) heteroarylheterocyclyl containing from 8-14 ring atoms, wherein:

(1) from 1-2 of the ring atoms of the heteroaryl portion is independently selected from N, NH, N(C 1 -C 3 alkyl), O, and S; and wherein said heteroaryl portion is optionally substituted with from 1-3 independently selected R b ; and

(2) from 1-2 of the ring atoms of the heterocyclyl portion is independently selected from N, NH, N(C 1 -C 6 alkyl), NC(O)(C 1 -C 6 alkyl), O, and S; and wherein said heterocyclyl portion is optionally substituted with from 1-3 independently selected R a ;

(j) heteroarylcycloalkyl containing from 8-14 ring atoms, wherein:

(1) from 1-2 of the ring atoms of the heteroaryl portion is independently selected from N, NH, N(C 1 -C 3 alkyl), O, and S; and wherein said heteroaryl portion is optionally substituted with from 1-3 independently selected R b ; and

(2) the cycloalkyl portion is optionally substituted with from 1-4 independently selected R a ;

(k) C 3 -C 8 cycloalkyl or C 3 -C 8 cycloalkenyl, each of which is optionally substituted with from 1-4 independently selected R a ; and

(l) C 7 -C 12 aralkyl, wherein the aryl portion is optionally substituted with from 1-4 independently selected R b ,

provided that one of R 10 and R 11 must be selected from (b), (c), (g), (h), (i), (j), and (k);

R 12 is:

(i) C6-C10 aryl that is optionally substituted with from 1-4 R b ; or

(ii) heteroaryl containing from 5-14 ring atoms, wherein from 1-6 of the ring atoms is independently selected from N, NH, N(C 1 -C 3 alkyl), O, and S; and wherein said heteroaryl is optionally substituted with from 1-4 R b ; or

(iii) C 1 -C 6 alkyl or C 1 -C 6 haloalkyl, each of which is substituted with from 1-3 R d ; or

(iv) C 8 -C 14 arylcycloalkyl, wherein:

(1) the aryl portion is optionally substituted with from 1-4 independently selected R b , and

(2) the cycloalkyl portion is optionally substituted with from 1-4 independently selected R a ; or

(v) arylheterocyclyl containing from 8-14 ring atoms, wherein:

(1) the aryl portion from is optionally substituted with from 1-4 independently selected R b , and

(2) from 1-2 of the ring atoms of the heterocyclyl portion is independently selected from N, NH, N(C 1 -C 6 alkyl), NC(O)(C 1 -C 6 alkyl), O, and S; and wherein said heterocyclyl portion is optionally substituted with from 1-3 independently selected R a ; or

(vi) heteroarylheterocyclyl containing from 8-14 ring atoms, wherein:

(1) from 1-2 of the ring atoms of the heteroaryl portion is independently selected from N, NH, N(C 1 -C 3 alkyl), O, and S; and wherein said heteroaryl portion is optionally substituted with from 1-3 independently selected R b ; and

(2) from 1-2 of the ring atoms of the heterocyclyl portion is independently selected from N, NH, N(C 1 -C 6 alkyl), NC(O)(C 1 -C 6 alkyl), O, and S; and wherein said heterocyclyl portion is optionally substituted with from 1-3 independently selected R a ;

or

(vii) heteroarylcycloalkyl containing from 8-14 ring atoms, wherein:

(1) from 1-2 of the ring atoms of the heteroaryl portion is independently selected from N, NH, N(C 1 -C 3 alkyl), O, and S; and wherein said heteroaryl portion is optionally substituted with from 1-3 independently selected R b ; and

(2) the cycloalkyl portion is optionally substituted with from 1-4 independently selected R a ;

R 13 is:

(i) C 6 -C 10 aryl that is optionally substituted with from 1-4 R b ; or

(ii) heteroaryl containing from 5-14 ring atoms, wherein from 1-6 of the ring atoms is independently selected from N, NH, N(C 1 -C 3 alkyl), O, and S; and wherein said heteroaryl is optionally substituted with from 1-4 R b ; or

(iii) C 8 -C 14 arylcycloalkyl, wherein:

(1) the aryl portion is optionally substituted with from 1-4 independently selected R b , and

(2) the cycloalkyl portion is optionally substituted with from 1-4 independently selected R a ;

or

(iv) arylheterocyclyl containing from 8-14 ring atoms, wherein:

(1) the aryl portion from is optionally substituted with from 1-4 independently selected R b , and

(2) from 1-2 of the ring atoms of the heterocyclyl portion is independently selected from N, NH, N(C 1 -C 6 alkyl), NC(O)(C 1 -C 6 alkyl), O, and S; and wherein said heterocyclyl portion is optionally substituted with from 1-3 independently selected R a ;

or

(v) heteroarylheterocyclyl containing from 8-14 ring atoms, wherein:

(1) from 1-2 of the ring atoms of the heteroaryl portion is independently selected from N, NH, N(C 1 -C 3 alkyl), O, and S; and wherein said heteroaryl portion is optionally substituted with from 1-3 independently selected R b ; and

(2) from 1-2 of the ring atoms of the heterocyclyl portion is independently selected from N, NH, N(C 1 -C 6 alkyl), NC(O)(C 1 -C 6 alkyl), O, and S; and wherein said heterocyclyl portion is optionally substituted with from 1-3 independently selected R a ;

or

(vi) heteroarylcycloalkyl containing from 8-14 ring atoms, wherein:

(1) from 1-2 of the ring atoms of the heteroaryl portion is independently selected from N, NH, N(C 1 -C 3 alkyl), O, and S; and wherein said heteroaryl portion is optionally substituted with from 1-3 independently selected R b ; and

(2) the cycloalkyl portion is optionally substituted with from 1-4 independently selected R a ;

R a at each occurrence is, independently selected from halo, hydroxyl, C 1 -C 6 alkoxy, C 1 -C 6 thioalkoxy, C 1 -C 6 haloalkoxy, C 1 -C 6 thiohaloalkoxy, oxo, thioxo, ═NH, ═N(C 1 -C 6 alkyl), C 1 -C 6 alkyl, C 1 -C 6 haloalkyl, —NH 2 , —NH(C 1 -C 6 alkyl), —N(C 1 -C 6 alkyl) 2 , —NHC(O)(C 1 -C 6 alkyl), and cyano;

R b at each occurrence is independently selected from the substituents delineated in (aa) through (dd) below:

(aa) C 1 -C 6 alkoxy; C 1 -C 6 haloalkoxy; C 1 -C 6 thioalkoxy; C 1 -C 6 thiohaloalkoxy; —O—(CH 2 ) 1-3 —[O(CH 2 ) 1-3 ] 1-3 —H; —C 1 -C 6 alkyl, C 1 -C 6 haloalkyl, —NH(C 1 -C 6 alkyl), —N(C 1 -C 6 alkyl) 2 , —NHC(O)(C 1 -C 6 alkyl), wherein the alkyl portion of each is optionally substituted with from 1-3 independently selected R e ;

(bb) halo; hydroxyl; cyano; nitro; —NH 2 ; azido; sulfhydryl; C 2 -C 6 alkenyl; C 2 -C 6 alkynyl; —C(O)H; —C(O)(C 1 -C 6 alkyl); —C(O) (C 1 -C 6 haloalkyl); —C(O)OH; —C(O)O(C 1 -C 6 alkyl); —C(O)NH 2 ; —C(O)NH(C 1 -C 6 alkyl); —C(O)N(C 1 -C 6 alkyl) 2 ; —SO 2 (C 1 -C 6 alkyl); —SO 2 NH 2 ; —SO 2 NH(C 1 -C 6 alkyl); —SO 2 N(C 1 -C 6 alkyl) 2 ;

(cc) C 3 -C 6 cycloalkyl or heterocyclyl containing from 5-6 ring atoms, wherein from 1-2 of the ring atoms of the heterocyclyl is independently selected from N, NH, N(C 1 -C 6 alkyl), NC(O)(C 1 -C 6 alkyl), O, and S; and wherein each of said phenyl and heterocyclyl is optionally substituted with from 1-3 independently selected R a ; and

(dd) phenyl or heteroaryl containing from 5-6 ring atoms, wherein from 1-2 of the ring atoms of the heteroaryl is independently selected from N, NH, N(C 1 -C 3 alkyl), O, and S; wherein each of said phenyl and heteroaryl is optionally substituted with from 1-3 substituents independently selected from halo; hydroxyl; cyano; nitro; —NH 2 ; —NH(C 1 -C 6 alkyl), —N(C 1 -C 6 alkyl) 2 , —NHC(O)(C 1 -C 6 alkyl), C 1 -C 6 alkoxy; C 1 -C 6 haloalkoxy; C 1 -C 6 thioalkoxy; C 1 -C 6 thiohaloalkoxy; C 1 -C 6 alkyl, and C 1 -C 6 haloalkyl;

R c at each occurrence is, independently selected from halo, C 1 -C 6 alkoxy, C 1 -C 6 thioalkoxy, C 1 -C 6 haloalkoxy, C 1 -C 6 thiohaloalkoxy, C 1 -C 6 alkyl, C 1 -C 6 haloalkyl, —NH 2 , —NH(C 1 -C 6 alkyl), —N(C 1 -C 6 alkyl) 2 , —NHC(O)(C 1 -C 6 alkyl), and cyano;

R d at each occurrence is, independently selected from hydroxyl, C 1 -C 6 alkoxy, C 1 -C 6 thioalkoxy, C 1 -C 6 haloalkoxy, C 1 -C 6 thiohaloalkoxy, C 1 -C 6 alkyl, C 1 -C 6 haloalkyl, —NH 2 , —NH(C 1 -C 6 alkyl), —N(C 1 -C 6 alkyl) 2 , —NHC(O)(C 1 -C 6 alkyl), and cyano; and

R e at each occurrence is, independently selected from hydroxyl, C 1 -C 6 alkoxy; C 1 -C 6 thioalkoxy; C 1 -C 6 haloalkoxy; C 1 -C 6 thiohaloalkoxy; —NH 2 ; —NH(C 1 -C 6 alkyl); —N(C 1 -C 6 alkyl) 2 ; —NHC(O)(C 1 -C 6 alkyl); cyano; —C(O)H; —C(O)(C 1 -C 6 alkyl); —C(O)(C 1 -C 6 haloalkyl); —C(O)OH; —C(O)O(C 1 -C 6 alkyl); —C(O)NH 2 ; —C(O)NH(C 1 -C 6 alkyl); —C(O)N(C 1 -C 6 alkyl) 2 ; —SO 2 (C 1 -C 6 alkyl); —SO 2 NH 2 ; —SO 2 NH(C 1 -C 6 alkyl); —SO 2 N(C 1 -C 6 alkyl) 2 ; and L 3 -(C 1 -C 6 alkylene)-biotin, where in L 3 is a —O—, —NH—, —NCH 3 —, —C(O)—, —C(O)NH—, —C(O)NCH 3 —, —NHC(O)—, or —NCH 3 C(O)—.

2. The method of claim 1 , wherein in the incubating step, the NAMPT is recombinantly produced.

3. The method of claim 1 , wherein in the incubating step, the NAMPT is present at about 0.1 to about 10 μM, about 0.5 to about 5 μM, or about 1 μM.

4. The method of claim 1 , further comprising incubating the test compound with nicotinamide, phosphoribosylpyrophosphate, alcohol dehydrogenase, nicotinamide mononucleotide adenylyl-transferase, and an alcohol.

5. The method of claim 4 , wherein the alcohol is ethanol.

6. The method of claim 1 , wherein the measuring step comprises determining an amount of nicotinamide adenine dinucleotide reduced form (NADH) and/or nicotinamide mononucleotide (NMN).

7. The method of claim 6 , wherein the amount of NADH and/or NMN is measured by ultra violet light, mass spectrometry or fluorescence.

8. The method of claim 7 , wherein the amount of NADH is measured by optical density 340 nm.

9. The method of claim 6 , wherein an increase in the amount of NADH and/or NMN is indicative of increased NAMPT activity.

10. The method of claim 1 , wherein the test compound having said cell-protective activity is determined to bind and/or activate the NAMPT.

11. The method of claim 1 , wherein the cell-protective activity is neuroprotective activity which includes one or more of: promoting survival, health, integrity, growth, development and/or function of neurons, protecting neurons from cell death, apoptosis and/or degeneration, and/or stimulating neurogenesis.

Assignments (5)
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Nov 30, 2015
From: PIEPER, ANDREW A
To: UNIVERSITY OF IOWA RESEARCH FOUNDATION
Reel/Frame 037166/0325 →
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Nov 30, 2015
From: MCKNIGHT, STEVEN L.; READY, JOSEPH M.
To: BOARD OF REGENTS OF THE UNIVERSITY OF TEXAS SYSTEM
Reel/Frame 037166/0450 →
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Nov 30, 2015
From: PIEPER, ANDREW A.
To: UNIVERSITY OF IOWA RESEARCH FOUNDATION
Reel/Frame 037166/0506 →
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Nov 30, 2015
From: MCKNIGHT, STEVEN L.; READY, JOSEPH M.
To: BOARD OF REGENTS OF THE UNIVERSITY OF TEXAS SYSTEM
Reel/Frame 037166/0551 →
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Nov 30, 2015
From: MCKNIGHT, STEVEN L.; READY, JOSEPH M.; WANG, GELIN; HAN, TING
To: BOARD OF REGENTS OF THE UNIVERSITY OF TEXAS SYSTEM
Reel/Frame 037166/0606 →
Continuity (6)
Division 14540006 · Nov 12, 2014
Continuation In Part PCTUS2014065058 · Nov 14, 2014
Provisional Application 61902680 · Nov 11, 2013
Provisional Application 61912625 · Dec 6, 2013
Provisional Application 61993328 · May 15, 2014
Related Publication 20170030897A1 · Feb 2, 2017